Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
![Essential](https://www.g2intelligence.com/wp-content/uploads/2023/11/Essential.png)
![62934_G2_Subscription Website Images_JL V1](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V1.png)
![Special-Report](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Report.png)
![62934_G2_Subscription Website Images_JL V12](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V12.png)
![Special-Analysis](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Analysis.png)
![Elite](https://www.g2intelligence.com/wp-content/uploads/2023/11/Elite.png)
Additional Business Intelligence Offerings
Lab Industry Advisor Subscriptions Include
![paper_magnifing_glass_512](https://www.g2intelligence.com/wp-content/uploads/2023/11/paper_magnifing_glass_512.png)
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
DOJ Reports $1.9 Billion in Health Care False Claims Act Recoveries for FY 2015
By Kelly A. Briganti, Editorial Director, G2 Intelligence Given the large False Claims settlements the laboratory sector has seen this year and the major nationwide Takedown initiatives, it's no surprise to hear the Department of Justice (DOJ) recovered $1.9...
LabCorp Acquires Pathology, Inc.
By Ron Shinkman, Editor, Laboratory Industry Report LabCorp will acquire a significant presence in women's health assays. The North Carolina-based LabCorp announced the acquisition of Pathology, Inc. on Dec. 10. Terms of the transaction were not disclosed. The lab...
Quest to Manage Barnabas Health’s Hospital Laboratories
By Ron Shinkman, Editor, Laboratory Industry Report Quest Diagnostics, which has been extending itself more into the operation of hospital laboratories in recent years, has just inked a deal to manage the labs owned by the largest hospital operator in its home...
FDA Workshop Addresses Security of Medical Devices
From - G2 Compliance Advisor
The U.S. Food and Drug Administration (FDA) is joining the cadre of government agencies calling attention to the cybersecurity risks of wireless, internet-and network-connected devices and…
Whistleblower Claims Lead to Big Settlements for Pathology Group and Laboratory
By Kelly A. Briganti, Editorial Director, G2 Intelligence Two separate False Claims Act cases initiated by whistleblowers have resulted in settlements for a North Carolina pathology group and a Wisconsin laboratory, its founders and a related company. In the first...